We’re incredibly proud to back Aeon in their €8.2 million funding round and to stand alongside them in their mission to transform preventive healthcare.

Every year, 41 million people die from non-communicable diseases.
Eighty percent of those deaths are preventable.
Yet today’s healthcare systems are too often reactive, fragmented, and tragically late.

Aeon is changing that — radically and with purpose.

Their platform integrates whole-body MRI, advanced blood biomarkers, genetic insights, physician expertise, and AI to detect over 500 health risks.
Early. Precisely. Often before symptoms appear.

Already, 11 percent of users have received a critical finding.
And so far, not a single false positive.
That’s not just technology. That’s lives changed. Lives saved.

What’s even more powerful is Aeon’s commitment to accessibility.
They are working toward full reimbursement through insurers to ensure this level of medical precision is available to more than just a privileged few.

They are not just building a product.
They are challenging the status quo.
And laying the foundation for a healthcare system that truly focuses on health.

We are honoured to support the Aeon team as they expand across Europe and continue building the future of proactive medicine.

Press Release